Why bluebird bio Stock Is Plunging Today

What happened?On Tuesday morning, gene therapy specialist bluebird bio (NASDAQ: BLUE) announced the temporary suspension of two of its clinical trials for LentiGlobin, an experimental gene therapy for sickle cell disease (SCD). Shares of the biotech company are falling off a clifRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario